StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $6.95 | $6.34 | -8.78% | 2.4M |
| 05-19 | $6.32 | $7.03 | +11.23% | 1.5M |
| 05-20 | $7.04 | $7.17 | +1.85% | 0.8M |
| 05-21 | $7.10 | $7.21 | +1.55% | 0.7M |
| 05-22 | $7.26 | $7.04 | -3.03% | 0.7M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2014 2014-02-28 | Q4 2013 2013-11-30 | Annual 2013 2013-08-31 | Q2 2013 2013-05-31 |
|---|---|---|---|---|
Revenue | $15.60K | $14.92K | $13.07K | $13.07K |
Operating Income | $-74.66K | $-71.53K | $-57.16K | $-44.79K |
Net Income | $-74.66K | $-71.53K | $-50.89K | $-44.79K |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $10.00K | $12.30K | $20.01K | $4.73K |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $2.63K | $6.17K | $15.29K | $664.00 |
Free Cash Flow OCF − CapEx | $-40.87K | $-37.33K | $-28.21K | $-22.84K |
Shares Outstanding | Not available | Not available | Not available | Not available |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
RLMD is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.